Acutaas Chemicals Limited (BOM:543349)
India
· Delayed Price · Currency is INR | Market Cap | 204.24B |
| Revenue (ttm) | 12.15B |
| Net Income (ttm) | 2.87B |
| Shares Out | n/a |
| EPS (ttm) | 34.76 |
| PE Ratio | 71.17 |
| Forward PE | 54.53 |
| Dividend | 1.50 (0.06%) |
| Ex-Dividend Date | Sep 18, 2025 |
| Volume | 47,105 |
| Average Volume | 34,191 |
| Open | 2,408.20 |
| Previous Close | 2,395.10 |
| Day's Range | 2,391.60 - 2,510.00 |
| 52-Week Range | 1,041.05 - 2,687.75 |
| Beta | n/a |
| RSI | 59.86 |
| Earnings Date | Apr 30, 2026 |
About Acutaas Chemicals
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist... [Read more]
Financial Performance
In fiscal year 2025, Acutaas Chemicals's revenue was 10.07 billion, an increase of 40.34% compared to the previous year's 7.17 billion. Earnings were 1.59 billion, an increase of 271.06%.
Financial StatementsNews
Acutaas Chemicals Transcript: Q3 25/26
Q3 FY 2026 saw revenue rise 43% year-over-year to INR 393.2 crore, with record-high margins and profit after tax exceeding INR 100 crore. Upgraded FY 2026 guidance projects 30% revenue growth and 32–35% EBITDA margin, driven by strong CDMO, battery, and semiconductor segments.
Acutaas Chemicals Transcript: Q2 25/26
Q2 FY26 saw 34% YOY revenue growth and significant margin expansion, led by pharma intermediates and CDMO. Battery chemicals and semiconductor JVs are set to drive future growth, with robust CapEx and strong cash reserves supporting expansion.
Acutaas Chemicals Transcript: Q1 25/26
Q1 FY 2026 revenue rose 17.3% YoY, led by pharma intermediates and strong margin expansion. Major CapEx in battery and semiconductor chemicals is underway, with new products and contracts set to drive growth. Management reaffirms 25% revenue growth guidance for FY 2026.
Acutaas Chemicals Transcript: Q4 24/25
Surpassed INR 1,000 crore in FY 2025 revenue, driven by 50% YoY growth in pharma intermediates and strong CDMO momentum. Margins expanded significantly, with robust cash flow and zero debt. FY 2026 targets 25% revenue growth, margin improvement, and new capacity ramp-up.
Acutaas Chemicals Transcript: Q3 24/25
Q3 FY25 saw 65% YoY revenue growth, driven by CDMO and pharma intermediates, with margins expanding and guidance raised to 35% growth for FY25. CapEx and capacity expansions are on track, and the company is positioned for strong multi-year growth across segments.
Acutaas Chemicals Transcript: Q2 24/25
Q2 FY 2025 saw 43.2% YoY revenue growth, driven by pharma intermediates and CDMO ramp-up, with gross and EBITDA margins improving. FY 2025 revenue growth guidance was raised to 30%, and CapEx projects are on track, despite sectoral demand and pricing headwinds.
Acutaas Chemicals Transcript: Q1 24/25
Revenue grew 16.6% year-over-year in Q1 FY 2025, led by advanced pharma intermediates and CDMO, while specialty chemicals saw modest growth. Management maintains 25% annual growth guidance, expects margin improvement, and continues to invest in capacity and sustainability.